Branched chain amino acid metabolism and microbiome in adolescents with obesity during weight loss therapy

Jessica R. McCann[1], Chengxin Yang[2], Nathan A. Bihlmeyer[3], Runshi Tang[11], Tracy Truong[2], Jie An[3], Jayanth Jawahar[1], Olga Ilkayeva[3, 10], Michael J. Muehlbauer[3], Zhengzheng Hu[1,7], Holly K. Dressman[1,7], Lisa Poppe[3], Joshua A. Granek[2,7], Lawrence A. David[1,7], Pixu Shi[2,7], Pinar Gumus Balikcioglu[4], Svati H. Shah[2,3,6], Sarah C. Armstrong[5,6], Christopher B. Newgard[3], Patrick C. Seed[8,9*], and John F. Rawls[1,7*]

[1] Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, USA

[2] Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA

[3] Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, USA

[4] Division of Pediatric Endocrinology and Diabetes, Duke University Medical Center, Durham, NC, USA

[5] Division of General Pediatrics, Duke University Medical Center, Durham, NC, USA

[6] Duke Clinical Research Institute, Duke University, Durham, NC, USA

[7] Duke Microbiome Center, Duke University School of Medicine, Durham, NC, USA

[8] Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

[9] Stanley Manne Children's Research Institute, Ann and Robert H. Lurie Children's Hospital, Chicago, IL, USA

[10] Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition, Duke University School of Medicine, Durham, NC, USA

[11] Department of Statistics, University of Wisconsin-Madison, Madison, WI

28   ***Corresponding Authors**

30
31
32

ABSTRACT

BACKGROUND: Obesity and weight loss in adults have been associated with distinct

metabolome and gut microbiome features, but the extent to which those associations apply to

adolescent stages remain unclear.

METHODS: The Pediatric Obesity Microbiome and Metabolism Study (POMMS) enrolled 220

adolescents aged 10-18 with severe obesity (OB) and 67 healthy weight controls (HWC). Blood,

stool, and clinical measures were collected at baseline and after a 6-month obesity intervention

for the OB group. Metabolomic profiling in serum using targeted quantitative mass spectrometry

and microbiome profiling in stool were performed, and those features were assessed for

associations with BMI, insulin resistance, and inflammation. Fecal microbiome transplants were

performed on germ-free mice using samples from both groups to assess effects on weight gain

and metabolic pathways.

RESULTS: Adolescents with OB exhibited higher serum branched-chain amino acid (BCAA)

but lower ketoacid metabolite (BCKA) levels compared with HWC. This pattern was sex- and

age-dependent, unlike adults with OB, who show elevated levels of both. Longitudinal analysis

identified metabolic and microbial features correlated with changes in health measures during the

intervention. The fecal microbiomes of adolescents with OB and HWC had similar diversity but

differed in membership and functional potential. FMT from both OB and HWC donors had

similar effects on mouse body weight, but specific taxa were linked to weight gain in FMT

recipients.

CONCLUSION: Adolescents with OB have unique metabolomic adaptations and microbiome

signatures compared to their HWC counterparts and adults with OB.

TRIAL REGISTRATION:

ClinicalTrials.gov Identifier: NCT03139877 (Observational Study) and NCT02959034

(Repository)

FUNDING SOURCES:

American Heart Association Grants: 17SFRN33670990, 20PRE35180195

National Institute of Diabetes and Digestive and Kidney Diseases Grant: R24-DK110492

INTRODUCTION

Current knowledge about the physiology of obesity and treatment response is dominated by studies conducted in adults. Since the 1960s, studies have established that elevation of circulating branched-chain amino acids (BCAA: valine, leucine, and isoleucine) and various products of their catabolism are associated with adult obesity, metabolic syndrome, and future development of T2D (1-3). The ketoacid metabolites of BCAA (BCKA) have been measured in fewer studies but are also reported to be elevated in adults with obesity (4, 5). Adults who lose weight via dietary and exercise interventions with or without bariatric surgery experience a reduction in BCAA and BCKA levels (6-8). BCAA-deficient diets in rodents confirm a causal relationship with obesity and T2D (9, 10). Circulating glutamate, a product of BCAA metabolism, is also associated with both insulin resistance and obesity in adults (11). Finally, some short and medium chain acylcarnitines, such as the C3 and C5 species generated from BCAA metabolism, are consistently found in a metabolite principal component associated with adult T2D and insulin resistance (2, 12). Together, these results establish that adults with obesity have a metabolic profile consisting of elevated BCAA, BCKA, and associated acylcarnitines and amino acids.

Adolescence is a critical window during which time successful treatment of obesity dramatically reduces the risk for adult obesity, T2D, and cardiovascular mortality, and significant reduction of childhood obesity by late adolescence reduces risk to levels similar to children who never experienced obesity (13, 14). A similar magnitude of weight loss in adults with obesity does not lead to the same degree of risk reduction, suggesting that obesity in earlier life may be driven by physiological mechanisms that are still reversible before adulthood. Yet,

little is known about how the metabolic pathways of obesity differ between adolescence and

adulthood.

Limited prior work has indicated that obesity in youth aged 4-19 years is characterized by

increased BCAA and acylcarnitine catabolism and changes in nucleotides, lysolipids, and

inflammatory markers also seen in adults with obesity, as well as reduced fatty acid catabolism

that may be unique to obesity in children (15). Recent work comparing male and female

adolescents with obesity in the age range of 12-18 years who underwent a 6-month lifestyle

intervention program suggests a sex difference in the baseline level of circulating BCKA, with

males having higher levels than females despite similar BMI profiles (16). In addition, a recent

study showed an elevation in urinary BCAA and BCKA levels in female adolescent subjects

with type 2 diabetes compared to obese, non-diabetic, or lean controls, accompanied by diversion

of tryptophan metabolism from the serotonin to the kynurenine pathway (17). These metabolic

indices may be related to the higher risk of T2D in obese adolescent females than in adolescent

males or relatively higher rates of anabolic metabolism in males. However, the similarities and

differences in obesity physiology between adolescents and adults remain unclear, especially with

respect to sex and age.

Several studies in adults have reported gut microbiome alterations associated with obesity

and related diseases (reviewed in (18)). Fecal microbiome transplant (FMT) from adult humans

with and without obesity to germ-free (GF) mouse recipients has indicated that the microbiome

can causally contribute to obesity and associated metabolic phenotypes. GF mice receiving FMT

from adult donors with obesity gain more weight, gain more fat mass, and have distinct

microbiota-linked changes to serum metabolite profiles than those receiving FMT from a healthy

weight adult donor (19-22). However, it remains unknown if the microbiome causally

contributes to obesity physiology during earlier adolescent stages. Based on the lack of gut

microbial diversity differences we observed in our preliminary cohort analysis (23) we

hypothesized that adolescent obesity would not be directly correlated with gut dysbiosis to the

same extent as observed in adults.

We established the Pediatric Obesity Microbiome and Metabolism Study (POMMS) to

test the hypothesis that adolescents with obesity have metabolic and microbiome characteristics

at baseline and following weight loss intervention that distinguish them from adults with obesity

(23). Our study cohort was drawn from the Duke Children's Healthy Lifestyles program, which

offers multi-component behavioral, pharmacotherapeutic, and surgical treatment options as per

the current American Academy of Pediatrics guidelines for youth aged 23 and younger with

obesity (24). By studying the microbiome and metabolome in this diverse population, we sought

to identify new prognostic and therapeutic targets for greater obesity-associated disease risk

reduction and reversibility in the most affected populations. Further, adolescents tend to be

treatment naïve. Thus, their clinical and metabolic measures are less complicated by drug effects.

The study design, data collection, and demographics of the POMMS cohort were previously

described (23). Here, we report our findings from the complete metabolome and microbiome

datasets at baseline and after intervention.

RESULTS

Baseline characteristics. The POMMS clinical cohort was recruited upon referral to the Duke

Healthy Lifestyles Clinic in Durham, North Carolina, USA. Details concerning recruitment,

treatment plans, and demographics of our study cohort have been previously reported (23) and

are summarized in Figure 1A and Supplemental Table 1. Participants with obesity (OB, n= 220)

and healthy weight controls (HWC, n= 67) were well-matched according to self-reported race

and ethnicity. However, the OB group was significantly more female-identifying and younger

than the HWC group (Supplemental Table 1). CRP, HbA1c, ALT, LDL cholesterol, triglyceride,

insulin, systolic and diastolic blood pressures, and triglyceride/HDL ratio were higher in the OB

group compared with the HWC group (Table 1). HDL cholesterol levels were lower in the OB

group as compared with the HWC group. Fasting glycerol levels were also significantly higher in

the OB group using a targeted lab analysis (Supplemental Table 1.1), suggesting higher levels of

lipolysis in adolescents with OB as compared with HWC (25). However, these two groups had

no significant difference in fasting glucose levels, suggesting that even though several metrics

associated with OB in adults were significantly higher in the OB cohort when compared to

HWC, high BMI alone is not enough to significantly confer a difference in fasting glucose

commonly observed in adults with obesity (26).

Serum metabolites reveal distinct adolescent sex- and age-dependent associations with

BMI, insulin resistance, and inflammation. In an adjusted analysis of serum metabolites in OB

and HWC adolescents at baseline, levels of BCAA valine (Val), the amino acids tyrosine (Tyr),

glutamine/glutamate (Glx), and phenylalanine (Phe), and C3 (propionyl, a bioproduct of BCAA

catabolism) and C8:1 acylcarnitines were all significantly and positively associated with BMI

measured as a percent of the BMI 95th percentile (%95th BMI) (27). In contrast, higher serum

levels of the amino acids glycine (Gly), serine (Ser), histidine (His), methionine (Met), and

several even chain acylcarnitines were significantly negatively associated with %95th BMI

(Figure 1C), as were the ketoacids of BCAAs, leucine (KIC) and isoleucine (KMV). This is in

notable contrast to adults in which these ketoacids are typically positively associated with

obesity and T2D (4, 7). Several of the metabolites associated with %95th BMI at baseline were

also associated with HOMA-IR at baseline, including those negatively associated (Gly, Ser, and

acylcarnitines C20 and C6-DC/C8-OH) and positively associated (Val, Tyr, Phe, Glx, C3) with

HOMA-IR (Figure 1D). HOMA-IR was also significantly positively associated with levels of

leucine/isoleucine (Leu/Ile) and proline (Pro) but was not associated with BCKA. In adults,

elevated BMI and HOMA-IR have similarly been associated with higher BCAA, Phe, Tyr, and

C3 acylcarnitine (2, 4, 5). However, adult BMI and HOMA-IR are also associated with high

levels of BCKA as noted above, but we did not observe this in our adolescent cohort. These data

suggest that adolescents with OB have metabolic features like adults with obesity including

higher BCAA and associated metabolites, but also display adaptations that differ from adults

including lower BCKA in association with high BMI.

In analyses of HbA1c, only the amino acids Leu/Ile, Phe, and Tyr were significantly

positively associated with HbA1c (Figure 1C); the acylcarnitines C3-C5, and BCKA KIV were

negatively (but not significantly) associated with higher HbA1c, again suggesting metabolites

associated with IR and OB in adults are not significantly associated with key clinical measures of

metabolic syndrome in our adolescent cohort. It should be noted that HbA1c is a predictive

measure for IR in adults, but its use as a measure of metabolic health during adolescence can

sometimes be difficult to interpret, as high levels can occur in adolescents with a normal weight

and fasting glucose profiles (28).

CRP, a clinical marker of general inflammation, significantly correlated with fewer

metabolites either positively (Val, Phe, Asx) or negatively (acylcarnitine C20, His, Gly, and

alanine Ala) at baseline (Figure 1E). Some of these significant CRP-metabolite associations were

similar in directionality to those with %95th BMI or HOMA-IR (Val, Phe, His, Gly, C20), whilst

others were unique to CRP (Asx) or exhibited reversed directionality compared to HOMA-IR

(Ala). Whereas only a subset of acylcarnitine species measured here were significantly

associated with these three clinical measures, we observed that most acylcarnitines were

generally positively correlated with CRP but negatively correlated with HOMA-IR and %95th

BMI. Therefore, the general association trend between most serum acylcarnitines and CRP is

inverse to that of %95th BMI, HbA1c, and HOMA-IR.

BCAA metabolism in adolescent obesity is sex and age dependent.

Prior work suggests that there is an interaction between obesity status, pubertal status, sex

and age that influences BCAA and their related metabolite levels (16). To further assess these

metabolic signatures in our adolescent cohort, we analyzed data stratified by OB v HWC status

and age on serum metabolite levels to identify factors that influence metabolite levels in our

cohort. We found initially that signatures associated with OB v HWC status were driven by

metabolite levels in HWC males (Figure 2, Supplemental Table 2). We also found that serum

levels of the BCAA, along with several other amino acids and acylcarnitines involved in BCAA

metabolism, were significantly varied by OB v HWC status and sex (Figure 2A). Males

generally had higher levels of most affected amino acids and their metabolites. When we

analyzed raw data and adjusted only for multiple comparisons, males with HWC status had

significantly higher levels of Leu/Ile, Glx, and the BCAA metabolite C3 than OB males, as well

as the ketoacids of Leu and Ile (KIC and KMV, respectively; Figure 2B-J). Following adjustment

for age and race, several of these relationships remained significant, including higher levels of

Leu/Ile, C8:1-OH/C6:1DC, C18, C20-OH/C18-DC, Met, His, Orn, and Cit in HWC males

compared with males with OB (Supplemental Table 2.1). Because adults with OB tend to have

higher levels of BCKA compared to HWC (4-8), we tested if the opposite trends in the

adolescent data were still seen in older adolescents by assessing metabolites affected by the

interaction of obesity, sex, age, and Tanner (pubertal) stage (29). We found that the amino acids

Leu/Ile, His, Orn, Val, Met, Cit, and Phe, and the acylcarnitines C18, C20-OH/C18-DC, C16,

C18:1, and C8:1-OH/C6:1DC were significantly affected by the overall interaction between

HWC v OB status and sex (Figure 3A, Supplemental Table 2). Second stage testing further

delineated the role of status and sex for each indicated metabolite (Supplemental Table 2.1).

Based on the interaction of Tanner stage and HWC v OB status, KMV (ketoacid of Ile) was

significantly associated with Tanner stages 4 and 5, suggesting that more mature teens had a

greater difference in serum levels of this ketoacid (Figure 3B, Supplemental Table 3). To test

whether BCKA are associated with sex and obesity at younger ages, we analyzed metabolite data

from the Hearts and Parks (HP) Study, which included children enrolled as early as age 5 (30). In

these analyses of children aged 5-9 years, we found that the ketoacid KMV was no longer

associated with sex in the younger children. Still, the BCAA acylcarnitine metabolite C3 was

associated with sex in the older age group after stratified analysis (Figure 3C). These results

indicate that obesity-associated differences in BCAA and related metabolite levels are sex-

dependent and emerge later in adolescence.

Microbiome alpha and beta diversity were similar between OB and HWC adolescents, but

taxa and microbial features were distinct between cohorts. We analyzed 16S rRNA gene

amplicon sequence data from 786 fecal samples covering 50 HWC participants at baseline, all 5

timepoints from 57 participants with OB that contributed fecal samples at 0, 1.5, 3, 4.5 and 6

months of the POMMS study, and at least 0 and 6 month timepoints from 140 participants in the

OB cohort. As in the interim analysis (23), we observed no significant differences in either alpha

or beta diversity based on HWC v OB status at baseline, sex, or age at entry (Supplemental

Figure 1A and data not shown). When we tested whether specific bacterial lineages might be

associated with %95th BMI at baseline, we found that relative abundance of several family-level

taxa were positively correlated with %95th BMI, while the HWC group had significantly higher

abundance in members of the Lachnospiraceae and Bacteroiodaceae compared with the OB

group (Supplemental Figure 1B).

To gain further insight into these microbial communities, shotgun DNA sequencing data were

obtained for 396 participant-derived fecal samples, including quality controls for sequencing

fidelity and sampling replication. High quality sequences were obtained for 140 OB at baseline

and 6 months, and 50 HWC participants at the baseline time point. Consistent with the 16S

rRNA data, alpha and beta diversity did not significantly differ between the OB and HWC

cohorts (Supplemental Figure 2), and profiles of the most abundant family- and species-level

taxa were generally similar between the two cohorts (Supplemental Figure 3). Further analysis

determined, however, that participants from the OB cohort had a significantly higher Firmicutes

to Bacteroidetes ratio than HWC (P= 0.001). ALDEx2 (31), ANCOM-BC (32), and corncob (33)

analyses were employed to identify differential taxa between the two groups at baseline. The

methods detected an increased relative abundance of genera *Ligilactobacillus* and reduced

Alistipes among the OB participants. Of the *Ligilactobacillus*, the species *L. ruminis* was most

prevalent (>90% of samples), and of *Alistipes*, the species *A. finegoldii* was found in most

samples (>90%). Notably, *Ligilactobacillus* and *Alistipes* abundance remained positively and

negatively correlated, respectively, with %95th BMI (Figure 4A).

To reduce data dimensionality, taxa and functional capacity of the gut microbiomes were

clustered using hierarchical clustering, and the resulting factors were associated with clinical

scores at baseline (Figure 4C, Supplemental Figure S4, and Supplemental Tables 4.1-4.3).

Though microbial species diversity was similar between the two cohorts at baseline

(Supplemental Figure 2), we identified two taxonomic clusters significantly associated with

either %95th BMI or CRP as continuous variables (Figure 4C, with factors defined in

Supplemental Tables 4.1-4.4). Further clustering of serum metabolomics, KEGG orthology

functions, and taxa revealed associations with clinical variables. We found several clusters of co-

varying taxa, genes, phages, and serum metabolites indicating that there is cross talk between

metabolomic status and the microbiome (Supplemental Figure 4, with weights and factors

defined in "Supplemental Tables – Factor Weights"). Using a random forest machine learning

model, we generated a model that predicts OB v HWC status, which was significantly enriched

for pathways involved in microbial amino acid synthesis, two-component signaling,

lipopolysaccharide biosynthesis, and bacterial cell membrane components. Notably, several

genes required for microbial synthesis of BCAA and tryptophan were independently identified as

significant contributors to this model (Supplemental Figure 5B and Supplemental Table 4.5),

mirroring prior research that associated gut microbial BCAA synthesis genes with T2D in adults

(34) and children with obesity (35). No factors were significantly associated with HOMA-IR

score at baseline (data not shown).

Donor-status independent metabolites and microbes were associated with weight gain and

percent adipose in FMT recipient mice. Previous FMT experiments demonstrated that

microbial content can confer phenotypic and metabolomic traits of the donor, at least

temporarily, to germ-free mouse (19-21) and human (36) recipients. However, all prior studies

that examined the role of the microbiota in obesity used fecal samples from adult donors. We

hypothesized that adolescent microbiota, influenced by host growth and development, are

optimized for peak energy harvest regardless of OB and HWC status, and that weight gain may

not differ between mice receiving FMT from HWC or OB donors. To test this, we chose FMT

samples of male and female donor adolescents from the HWC group, with %95th BMI that

ranged from the 20th to the 80th percentile, and from the OB group (see Supplemental Table 5 for

FMT donor demographics). Male C57Bl/6 mice aged 5-7 weeks were weighed, gavaged with

150-200 µl of donor slurry (Figure 5A), housed under gnotobiotic conditions and fed a sterilized

standard chow diet ad libitum, and then euthanized at 2 weeks post gavage. We weighed the ex-

germ-free mice every 3-4 days post gavage (Figure 5B). While there was a non-significant trend

towards more weight gained (Figure 5D) and heavier epididymal fat pads (Figure 5E) in mice

that received donor slurry from adolescents with OB, we did not observe significant changes in

weight gain or fat pad mass associated with donor OB vs HWC status or with sex or race of

donor (data not shown). The strongest predictor of weight gain across all recipient mice was the

starting weight of the recipient (R^2=0.72, p<0.0001). Comparing metabolite profiles across all

recipient mice, levels of serum amino acids Gly, Tyr, Asx, and Arg, as well as acylcarnitines

C16:1, C10:3, C8:1C4-DC/Ci4-DC were negatively associated with weight gained (Figure 5C).

We were intrigued to see that microbiome samples from some individual adolescent

donors were able to confer greater weight gain over others, raising the possibility that some

transplanted human gut microbes might be associated with weight gain. Indeed, we did detect a

microbial signature associated with weight gained, percent adipose (Table 2), and serum

metabolite features. Fecal microbial alpha diversity was significantly higher in mice receiving

donor microbiomes from HWC donors than OB donor recipients (Supplemental Figure 6C). We

found Bray-Curtis dissimilarity to be significantly associated with percent weight gain and donor

weight group (p-values <0.01) but not adipose percent change (p-value >0.1). We also saw

significant engraftment of *Akkermansia*, *Ruminoccocus*, and *Bacteroides* in fecal samples 2

weeks post gavage when compared to the composition of the donor sample, and a relative

decrease in members of the *Blautia* genus throughout engraftment (Supplemental Figure 6B).

Only two taxa were significantly negatively associated with weight gain across all recipient mice

– ASV 153 *Barnesiella* sp. (log2 fold change -0.80, padj. 5.2^{-13}) and ASV 21 *Collinsinella*

aerofaciens (log2 fold change -0.19, padj 0.02). We also found several microbes significantly

associated with clusters of co-varying metabolites (Supplemental Figure 6C and Supplemental

Table 5.2). Many of these microbes are significantly associated with metabolite cluster 1,

comprised of mostly even medium- to long-chain acylcarnitines. Cluster 2 was defined by the

BCAA valine, BCKA KIC, KIV, and KMV, along with BCAA metabolite 3-HIB (37). This

metabolite cluster was both positively and negatively associated with several *Blautia* and

Bacteroides ASVs (Figure 5G).

Serum levels of aromatic and branched chain amino acids are positively associated with

BMI and IR over the 6 month observational study period while levels of even chain

acylcarnitines are negatively correlated with change in BMI and IR. We next sought to

determine whether metabolic shifts co-occur with improvements in health metrics during weight

loss intervention. Using adjusted linear regression models, we examined whether a change in

metabolites correlated with a positive or negative change in BMI, HOMA-IR, or CRP. We

observed that, in general, changes in aromatic and branched chain amino acids were positively

associated with change in BMI, HOMA-IR, and HbA1c over the 6 months observational study

period, while changes in several even chain acylcarnitines and glycine were negatively

associated with changes in BMI and HOMA-IR. While the majority of participants either

maintained or reduced their %95th BMI score, HOMA-IR increased for most participants over

the observation period (Figure 6A-B and Supplemental Figure 8) which is a common

phenomenon during adolescence (38-40). While amino acids were not associated with CRP,

several acylcarnitine metabolites were positively associated with CRP. Changes in these

acylcarnitines were negatively associated with changes in BMI or HOMA-IR (Figure 6DF).

Microbiome taxa and pathways at baseline predict change in health measures over the

observational period, while distinct sets of taxa and features are associated with change in

CRP. We analyzed the metagenomic data to determine if there were any microbial taxa or

pathways at baseline that were significantly associated with change in BMI, HOMA-IR, CRP, or

HbA1c. While there were no significant associations with change in HOMA-IR, we found that

relative abundance of several microbial taxa at baseline were predictive of changes in BMI,

HbA1C, or CRP levels, with some taxa shared between changes in 2 measures (Figure 7B). For

example, *Bacteroides thetaiotaomicron*, *finegoldii*, and *uniformis* as well as *Parabacteroides*

distasonis and *merdae* were all associated with change in CRP and %95th BMI, but often in

opposite directions. In addition, *Anaerostipes hadrus*, *Blautia producta*, and *Escherichia* virus

Lambda_4A7 were all commonly associated with a change in HbA1c (Figure S7C) and CRP

(Figure S7D). Notably, a high number of taxa (93) were significantly associated with changes in

CRP suggesting that the subset of microbes that potentially predict changes in this inflammatory

marker are more abundant when compared to those associated with strictly with BMI or other

metabolic health indicators.

DISCUSSION

Based on studies of adult obesity indicating that the gut microbiome plays a substantial

role in driving obesity-associated phenotypes, similar microbiome and metabolic coupling has

been presumed in adolescent obesity. We studied a cohort of adolescents with and without

obesity to compare their metabolic and microbiome states with the hypothesis that the obesity-

associated adolescent metabolome and microbiome differ from that reported in adults with

obesity. We further postulated that the adolescent metabolic rearrangement associated with

obesity would not be associated with gut dysbiosis to the same extent as observed in adults,

suggesting a decoupling of metabolic shaping in adolescent obesity and the gut microbiome.

BCAA and BCKA have an inversely correlated signature in obesity that is unique to

adolescents. In our study of adolescents with obesity, we found that serum levels of the BCAA

and their direct metabolites, the BCKA, significantly differed between the OB and HWC cohorts,

but the BCKA skewed higher in the HWC group. At the same time, BCAA were higher among

adolescents with obesity. Circulating levels of BCAA have been associated with obesity, IR, and

T2D in adults since the late 1960s (1, 2, 41). At baseline, BCAA and aromatic amino levels are

prognostic for the development of T2D in adults in long-term studies (3, 42), and this same

metabolite cluster also predicts improvements in HOMA-IR in response to weight loss (43).

While circulating amino acids are often measured in metabolite studies of adults, it is less

common that those data sets also include BCKA measurements. When measured, BCKA levels

tend to mirror BCAA levels in adults with obesity, with both being higher than in HWC (7) and

both dropping significantly after effective treatments for obesity and T2D such as an exercise-

based intervention (6) or bariatric surgery (44, 45). This may be related to obesity-driven

changes in expression and activity of the kinase (branched-chain ketoacid dehydrogenase kinase,

BCKDK) and phosphatase (protein phosphatase Mg2+/Mn2+ dependent 1 kinase, PPM1K)

enzymes that control phosphorylation state and activity of branched-chain ketoacid

dehydrogenase (BCKDH), the rate-limiting enzyme of BCAA catabolism (46, 47). Similarly,

studies in adult rodent models, including *ob/ob* mice and Zucker-obese rats, show combined

higher levels of BCAA and BCKA in the obese state (7, 47). Our finding of anticorrelated

BCAA and BCKA levels in adolescents with obesity indicates a metabolic phenotype during

these critical early stages that is distinct from that found in adults with obesity. We speculate this

could be due to flexible regulation of PPM1K/BCKDK in adolescents allowing for BCAA

catabolism even with higher circulating BCAA, or patterns of organ-specific BCAA metabolism

in adolescents that are distinct from what has been observed in adults. In agreement with our

results, a recent study in adolescents suggested that high BCAA and low Gly should be included

as part of a metabolic signature that could predict β-cell failure (48).

367   We found that the intersection of sex and obesity status plays a significant role in BCAA

and BCKA levels. Our data suggest that these effects do not emerge until puberty onset, as we

found that there were few sex-based differences in BCAA-BCKA metabolites in kids aged 5-9

years from the AHA Hearts and Parks Study (30). Our observation of sexual dimorphism in

circulating levels of BCAA and their metabolism in adolescents is in accord with previous

studies. Kobayashi and colleagues demonstrated that female sex hormones affected the diurnal

regulation of the enzyme complex responsible for BCAA metabolism in rat liver, whereas

gonadectomy of adult male rats did not affect circadian BCAA metabolism (8). Human data

examining the serum metabolomic differences of 1756 adult participants (903 females and 853

males) from the population-based Cooperative Health Research in the Region of Augsburg

Germany (KORA) F4 study suggested that BCAA metabolites were significantly higher in males

and were significantly associated with male sex when taken as a group (49). In another study,

exercising men had higher rates of leucine oxidation than women (50). Focusing on children and

teens, Newbern and colleagues (51) published that in a cohort of 82 teens with obesity, BCAA

levels and byproducts of BCAA catabolism are higher in teen boys with obesity than in girls of

comparable BMI. A subsequent study by the same group found that plasma levels of KMV, the

ketoacid of isoleucine, went down in males but not in females when measured at the 6-month

follow-up visit (16). The mechanisms underlying these emerging sex- and age-associated

differences in BCAA metabolism remain unknown, but they could represent useful diagnostic

and prognostic markers of obesity-associated pathologic progression.

Lower serum glycine is a common signature of obesity in adolescents and adults. We also

found that serum glycine levels were significantly lower in adolescents with obesity when

compared to the HWC group. This observation has been documented in adult obesity (52-54),

and glycine levels increase after weight loss and improvement with insulin sensitivity (6, 44, 45,

55, 56). A recent study showed that elevations of BCAA in obesity activate glycine consumption

to replenish pyruvate needed for the alanine transaminase reaction and nitrogen unloading in

skeletal muscle (57) (Figure 2A). Treatment with a specific BCAT inhibitor that interferes with

BCAA transamination increases muscle and plasma glycine levels in Zucker fatty rats (10). Our

data suggest that the reciprocal relationship between BCAA catabolism and glycine levels exists

in adolescents despite their divergent BCKA signatures.

Acylcarnitine data from adult humans suggests that serum or plasma levels of C3-C5

species, which are derived from the metabolism of BCAA and other amino acids (58), often

cluster in principal component metabolite factors along with the BCAA and aromatic amino

acids, with higher levels in obesity, insulin resistance, and T2D (2, 43, 59). Low-grade chronic

inflammation is a hallmark of T2D (60, 61) and obesity (62), and CRP levels drop with weight

loss (63, 64). Herein, we identified an acylcarnitine signature that included associated with CRP

levels at baseline (Figure 1) and with change in CRP during the observational period (Figure 6)

that was distinct from the acylcarnitine species associated with both baseline and during-study

changes in BMI and HOMA-IR. Fewer data sets incorporate metabolites when comparing HWC

and OB in children and adolescents. One of the most comprehensive reports describes a cohort of

803 Hispanic children in the Viva la Familia study, ranging in age from 4-19y and split between

HWC and OB at a single timepoint (15). They examined 304 named serum metabolites and

found that their OB subjects had increased BCAA and acylcarnitine metabolites and increased

inflammation markers. The Viva la Familia study did not include BCKA measurements, nor did

it include longitudinal sampling or interventions. The data sets reported here therefore provide

new insights into the relationships between BCAA, BCKA, and acylcarnitine species in the

context of pediatric obesity and intervention outcomes.

Functional microbiome signatures are associated with obesity and metabolic signatures.

Fecal microbiome transplants from adult lean donors and donors with obesity into germ-free

mice demonstrate that the microbiome can contribute to weight gain and adiposity and affect the

serum metabolomic profiles of the recipients (19, 21, 65). While we did not observe significant

differences in alpha and beta diversity between our adolescent case and control groups, the

functional suite of genes represented in the microbiome associated with obesity in adolescence

may still play a role in the serum availability of some obesity-related metabolic biomarkers. We

found significant associations between BMI status and microbial genetic ability to synthesize

several amino acids including the BCAA and tryptophan (Supplemental Figure 5B). Research in

pigs suggests that approximately 30% of dietary glycine is consumed by the small intestinal

microbiota (66, 67), while other work in both conventionally-raised and germ-free mice and rats

suggests that the gut microbiome contributes on the order of grams per day of essential amino

acids to the nutritional pool (65). In the future, longitudinal studies in pre-clinical models of diet-

induced obesity could be used to clarify the role of age and sex in BCAA and acylcarnitine

metabolism, to investigate mechanisms underlying the transition from high BCAA - low BCKA

in youth to high BCAA - high BCKA in adult obesity, and the contributions of the microbiome

to those metabolic shifts.

Metabolites and microbiome associations in children and adolescents – microbiome

across HWC and OB adolescents is less differential than in adult cohorts. Our results

provide important insights into the composition and function of the gut microbiome of pediatric

obesity. Previous studies suggest that the gut microbiome undergoes changes between

adolescence and adulthood in healthy individuals (68). Adults with obesity and healthy weight

display substantial differences in gut microbiome diversity and composition (19, 69, 70), and

those differences are distinct from adolescents with obesity or healthy weight (71). Our

comparisons of adolescents with obesity and healthy weight detected no differences in diversity

and limited differences in composition and functional potential. Previous studies examining the

role of the microbiome in the development of obesity in germ-free animal models demonstrated

that the microbiome from adult donors with OB contributes to more weight gain, higher

adiposity, and higher circulating BCAA compared to a microbiome transplant from a lean adult

donor (19, 72). However, there was no specific association between weight gain and donor BMI

in our FMT studies here from adolescent donors. Together, these results raise the possibility that

the gut microbiomes harbored by adolescents with obesity do not yet have sufficient

compositional or functional changes to causally affect host metabolism, whereas microbiome

changes and causal consequences increase progressively as individuals with obesity progress into

adulthood. In the future, it will be important to determine if the ability of the gut microbiome to

contribute to obesity phenotypes is due to microbiome functional differences (69) or differences

in host growth and physiology during that critical stage. The resulting information could inform

efforts to target the microbiome in treatment of obesity.

Recently, several medications were FDA-approved for the treatment of obesity in

adolescents aged 12 and older (24). While these agents are remarkably effective in reducing

body mass index (BMI), questions remain about the necessary duration of treatment. Some

studies have suggested that a normalization of BMI prior to adulthood, in effect, "resets" the

metabolic pathways and may offer hope for these teens to avoid the need for lifelong medication.

In the future, it will be interesting to determine how these newly approved medications affect the

distinct metabolic and microbial phenotypes described here.

One limitation of this study is that we did not have longitudinal sampling of any HWC

adolescent to examine any changes in insulin resistance associated with typical adolescence to

compare to adolescents with OB in our cohort (38-40). Another limitation is that our linear

regression data associations between metabolites and clinical values were only adjusted for

demographics and not multiple comparisons, so while relationships seem strong, the reported P

values are nominal to generate hypotheses that could be further evaluated in murine functional

models.

In conclusion, we found that adolescents with OB have unique metabolomic adaptations

when compared to their HWC counterparts and adults with OB. We also found that while both

OB and HWC teens had similar measures of gut microbiome diversity, there were distinct

microbial taxa and functional differences that defined OB v HWC status. We also found that the

suite of metabolites and gut microbial taxa associated with inflammatory status as measured by

CRP level had little overlap with those associated with insulin resistance scores and BMI.

Longitudinal analysis revealed metabolic and microbial features that correlate with or predict

changes in health measures over the observational period. Data derived from this cohort will help

to develop an improved understanding of the physiological pathways of adolescent obesity and

may provide insights that will inform future clinical decision-making.

METHODS

Sex as a biological variable. Both male and female participants were included in this study. All

relevant analyses were adjusted for sex, age, and race.

Study approval: Recruitment of participants and handling of clinical samples was approved as

part of the Pediatric Obesity Microbiome and Metabolism Study (POMMS; Clinical trial

identifier # NCT03139877) and described in detail in (23). Written informed consent was

received prior to participation and prior to inclusion of serum and fecal samples for further study

in the POMMS biobank. Data, serum, and stool samples from the study participants have been

banked and are available as a repository (Clinical trial identifier #NCT02959034) for further

research as described at https://sites.duke.edu/pomms. All animal experiments were performed

either at the Duke University Gnotobiotic Core or in the National Gnotobiotic Rodent Research

Center at the Center for Gastrointestinal Biology and Disease at the University of North Carolina

Chapel Hill in AAALAC-accredited facilities and according to IACUC-approved protocols.

Serum metabolomics: Serum metabolomic samples from the Hearts and Parks study (30) were

randomized and analyzed with the POMMS cohort samples to reduce drift from batch effects.

All serum metabolomics assays were performed at the Duke Molecular Physiology Institute.

Serum samples were randomized and analyzed for the conventional metabolites nonesterified

fatty acids (NEFA), glucose, insulin, glycerol, blood urea nitrogen (BUN), 3-hydroxybutyrate (3-

HB), total ketones, triglycerides, and uric acid. The samples were run in seven daily batches of

approximately 76 sera per batch. Samples were run on a Beckman autoanalyzer from individual

tubes, with pooled serum controls inserted at the beginning, middle, and end of the sequence.

Reagents for measuring for total ketones, 3-HB, and NEFA were from Fujifilm (Osaka, Japan).

Samples were additionally assayed for insulin using kits from Meso Scale Discovery (Rockville,

MD). All samples were refrozen afterwards for later insulin immunoassays on 96-well plates.

Corresponding to each batch of metabolites were two insulin plates (e.g. 1-2 for Batch 1, 3-4 for

Batch 2, and so on) on which the 76 samples were assayed, 38 per plate. Controls were run

twice on each insulin plate, placed at the beginning and end. Insulin was measured by

immunoassay using reagents and electrochemiluminescent imager from Meso Scale Discovery

(Rockville, MD). Glucose was measured on a Beckman DxC 600 clinical analyzer (Brea, CA).

HOMA-IR was calculated as (fasting insulin in units/liter x fasting glucose in mg/deciliter)/405

(73).

Serum samples were analyzed for amino acids and acylcarnitines in a targeted assay

using labeled standards as described (23). BCKA were analyzed by LC-MS/MS as described

(10). Briefly, 20 µl of plasma containing isotopically labeled internal standards KIC-d3, KIV-

5C13 (Cambridge Isotope Laboratories), and KMV-d8 (Toronto Research Chemicals) was

precipitated with 150 µl of 3M PCA. 200 µl of 25 M o-phenylenediamine (OPD) in 3M HCl was

added to the supernatants, and the samples were incubated at 80°C for 20 minutes. Keto acids

were extracted with ethyl acetate as previously described (74). The extracts were dried under

nitrogen, reconstituted in 200 mM ammonium acetate, and analyzed on a Waters Xevo TQ-S

triple quadrupole mass spectrometer coupled to a Waters Acquity UPLC system. The analytical

column (Waters Acquity UPLC BEH C18 Column, 1.7 μm, 2.1 × 50 mm) was used at 30°C. 10

μl of the sample was injected onto the column and eluted at a flow rate of 0.4 ml/min. The

gradient consisted of 45% eluent A (5 mM ammonium acetate in water) and 55% eluent B

(methanol) for 2 min., followed by a linear gradient to 95% B from 2 to 2.5 min., held at 95% B

for 0.7 min., returned to 45% A, and then the column was re-equilibrated at initial conditions for

1 minute. The total run time was 4.7 min. Mass transitions of m/z 203 → 161 (KIC), 206 → 161

(KIC-d3), 189 → 174 (KIV), 194 → 178 (KIV-5C13), 203 → 174 (KMV), and 211 → 177

(KMV-d8) were monitored in a positive ion electrospray ionization mode.

Fecal DNA preparation and sequencing: Fecal DNA was collected and aliquoted as described

(23). DNA was recovered from approximately 200mg of fecal material using the DNeasy Power

Soil Pro kit (Qiagen). Bacterial community composition in isolated DNA samples was

characterized by amplification of the V4 variable region of the 16S rRNA gene by polymerase

chain reaction using the forward primer 515 and reverse primer 806 following the Earth

Microbiome Project protocol (http://www.earthmicrobiome.org/). These primers (515F and

806R) carry unique barcodes that allow for multiplexed sequencing. Concentration of the PCR

products was measured using a Qubit dsDNA HS assay kit (ThermoFisher, Q32854) and a

Promega GloMax plate reader. Equimolar 16S rRNA gene PCR products for up to 384 samples

were pooled prior to sequencing. Sequencing was performed by the Duke Sequencing and

Genomic Technologies (SGT) Shared Resource on an Illumina NovaSeq instrument configured

for 250 base-pair paired-end sequencing runs on a S Prime lane. Fecal DNA extraction, 16S

rRNA library preparation, and sequencing, was performed at the Duke Microbiome Core

laboratories. Taxa were identified using DADA2 (75) and resulting data was analyzed as

described in the Statistical Analysis section.

Fecal DNA from a subset of 396 samples was submitted for metagenomic sequencing at the

Novogene Corporation, Inc., using the following protocol. Genomic DNA was randomly

fragmented by sonication, then DNA fragments were end polished, A-tailed, and ligated with the

full-length adapters of Illumina sequencing, and followed by further PCR amplification with P5

and indexed P7 oligos. The PCR products as the final construction of the libraries were purified

with AMPure XP system. Then libraries were checked for size distribution by Agilent 2100

Bioanalyzer (Agilent Technologies, CA, USA), and quantified by real-time PCR to meet the

criteria of 3 nM. The qualified libraries were fed into Illumina NovaSeq sequencers after pooling

according to effective concentration and expected data volume. The raw sequenced reads were

then filtered to remove reads that contained adapters, reads containing greater than 10%

unidentified bases, and reads with a quality score <5, or over 50% of the total bases. This

resulted in a total output of 2871.0 Gb of raw data.

Fecal microbiome transplant experiments: Gnotobiotic experiments were conducted at the

Duke University Gnotobiotic Core Facility or the National Gnotobiotic Rodent Resource Center

in the Center for Gastrointestinal Biology and Disease at the University of North Carolina at

Chapel Hill. Human fecal samples were prepared for animal gavage as described (76). Briefly,

upon receipt, samples were initially frozen at -80°C and then thawed, opened in a flexible film

anaerobic chamber (Coy Laboratory Products, Grass Lake, Michigan), homogenized with a

sterile plastic loop, and distributed into 2 ml cryovials in ~200 mg aliquots without preservative.

Samples were then stored at -80°C. Immediately before fecal transplant, samples were thawed,

resuspended into 10% weight per volume sterile PBS +0.05% cysteine, vortexed repeatedly,

allowed to settle at room temp for 5-10 min, and supernatant was then removed for gavage.

Three, four, or five male germ-free C57BL/6 mice between 5-7 weeks of age received between

150 and 200 µl of gavage slurry for each human sample administered. Mice were then housed

with ALPHA-Dri (Shepherd Specialty Papers) bedding for two weeks in sterile filter top cages

and fed autoclaved Teklad 2020SX diet (Envigo) and water ad libitum. Mice were weighed at

gavage and every 3-4 days following fecal transplant. At 2 weeks, mice were euthanized by

isoflurane overdose and immediately exsanguinated by cardiac puncture. Fecal samples and

tissues were removed and immediately snap frozen in liquid nitrogen, with between 5- and 7-min

elapsing between euthanasia and complete tissue removal. Serum and tissue targeted metabolites

were measured as described above and as previously published (23).

Statistical Analysis. Clinical lab measures and targeted metabolites were log-transformed to

ensure normality. Any metabolite with missing values (i.e. below the lower limits of

quantification) in >25% of samples was not further analyzed. For the remaining metabolites,

values below limit of quantification were imputed at half the minimum observed result (77).

Logistic regression models were used to test association between each clinical lab measure with

OB vs. HWC groups, controlling for age, sex, and race/ethnicity. To evaluate the metabolic

status of study participants, serum levels of 65 targeted metabolites were investigated for

associations with baseline %95th BMI, HOMA-IR score, HbA1c, and CRP using linear

regression models adjusting for age, sex, and race/ethnicity. Next, we assessed whether the

association between case-control status and each metabolite varied by age, sex, or race using

linear regression model with the interaction between status and age, sex, or race in separate

models. If the overall interaction was statistically significant (nominal p<0.05), pairwise

comparisons were reported. Lastly, the association between change in each clinical outcome

(%95th BMI, HOMA-IR score, HbA1C, and CRP) and change in each metabolite between

baseline and 6-months were assessed using linear regression models adjusting for age, sex,

race/ethnicity, and baseline clinical outcome. All analyses were conducted in R 4.1 (R Core

Team, 2022). Significance values were set at p<0.05 throughout. Microbiome data was analyzed

as follows. Spearman correlation was used to assess the association of alpha diversity metrics

(Observed species, Shannon index, Faith phylogenetic diversity) with mouse or human

physiologic measures, and Wilcoxon rank sum test was used to determine significant differences

between diversity metrics. Principal coordinate analysis with Bray-Curtis dissimilarity was used

to determine differences in overall microbial composition between gavage and fecal samples as

well as a clear clustering of fecal samples by donor and compositional differences were

determined by PERMANOVA (R package vegan). Hierarchical clustering (R package hclust,

default setting) was used to cluster metabolites as well as species in the metagenomic data set.

Taxa were assembled, annotated, and functionally characterized using Kaiju (78) and HUMAnN

(79) pipelines. Differential abundance analysis of ASVs with relative abundance above 0.1% in

at least 20% of the samples (R package ANCOMBC) was performed for donor weight group,

percent weight gain, and adipose percentage change, respectively, as well as for metabolite

factors jointly. The Benjamini-Hochberg method was applied to control the false discovery rate

(FDR) at 0.05 for multiple comparisons of ASVs. Random forests machine learning was (80)

used to model associations between fecal metagenomic taxa or functional genes and clinical

measures.

Data availability. Raw unprocessed and log-transformed data can be found in Supplemental

Data attached to this article. All raw sequencing data can be accessed via the NIH Sequence

Read Archive at Accession number (**number forthcoming).** Any other data and R code will be

shared upon request.

ACKNOWLEDGEMENTS:

The authors are grateful to Kristin Cleveland, Jamison Cameron, Brittany McAdams, and staff in

the Duke Gnotobiotic Core in the Division of Laboratory Animal Resources in the Duke

University School of Medicine, and Jeremy Herzog, Josh Marc Frost, and R. Balfour Sartor in

the National Gnotobiotic Rodent Resource Center in the Center for Gastrointestinal Biology and

Disease at the University of North Carolina at Chapel Hill which is supported by P30-

DK034987. We also thank staff at the Duke Microbiome Core laboratories for their assistance in

preparing samples for high throughput sequencing.

 TABLES

 Table 1. Baseline clinical lab values in OB versus HWC groups.

	HWC	OB	Total	OB/HWC geometric means (95% CI)	P-value*
	N=67	**N=220**	**N=287**		
ALT				1.65 (1.43, 1.89)	<0.001
Mean (SD)	14.6 (6.7)	24.7 (31.8)	22.9 (29.1)		
Median (Q1, Q3)	13.0 (11.0, 15.2)	20.0 (15.0, 25.0)	18.0 (14.0, 24.0)		
(Min, Max)	(6.0, 44.0)	(10.0, 456.0)	(6.0, 456.0)		
Missing	19 (28.4%)	4 (1.8%)	23 (8.0%)		
HbA1c				1.04 (1.01, 1.07)	0.007
Mean (SD)	5.3 (0.3)	5.6 (0.6)	5.5 (0.5)		
Median (Q1, Q3)	5.3 (5.2, 5.5)	5.5 (5.3, 5.7)	5.5 (5.2, 5.7)		
(Min, Max)	(4.4, 6.0)	(4.5, 11.7)	(4.4, 11.7)		
Missing	20 (29.9%)	10 (4.5%)	30 (10.5%)		
LDL				1.16 (1.05, 1.28)	0.003
Mean (SD)	88.0 (27.3)	97.0 (25.7)	95.3 (26.2)		
Median (Q1, Q3)	82.0 (72.0, 101.0)	94.0 (80.2, 111.0)	92.0 (78.0, 110.0)		
(Min, Max)	(38.0, 168.0)	(9.0, 195.0)	(9.0, 195.0)		
Missing	18 (26.9%)	6 (2.7%)	24 (8.4%)		
HDL				0.84 (0.78, 0.90)	<0.001
Mean (SD)	53.7 (12.3)	45.9 (10.1)	47.3 (10.9)		
Median (Q1, Q3)	51.0 (45.0, 59.0)	45.0 (39.0, 52.0)	46.0 (40.0, 53.0)		
(Min, Max)	(36.0, 100.0)	(27.0, 77.0)	(27.0, 100.0)		
Missing	18 (26.9%)	5 (2.3%)	23 (8.0%)		
Triglyceride				1.31 (1.14, 1.52)	<0.001
Mean (SD)	84.3 (43.6)	111.6 (56.7)	106.5 (55.4)		
Median (Q1, Q3)	72.0 (52.0, 97.0)	97.0 (73.0, 139.0)	91.0 (69.0, 133.8)		
(Min, Max)	(29.0, 223.0)	(22.0, 404.0)	(22.0, 404.0)		
Missing	18 (26.9%)	5 (2.3%)	23 (8.0%)		
TG/HDL ratio				1.57 (1.32, 1.87)	<0.001

Mean (SD)	1.7 (1.1)	2.6 (1.7)	2.5 (1.6)		
Median (Q1, Q3)	1.3 (0.9, 2.1)	2.1 (1.5, 3.2)	2.0 (1.3, 3.1)		
(Min, Max)	(0.5, 5.9)	(0.4, 11.9)	(0.4, 11.9)		
Missing	18 (26.9%)	5 (2.3%)	23 (8.0%)		
C-reactive protein				6.58 (4.34, 9.97)	<0.001
Mean (SD)	0.2 (0.7)	0.6 (0.9)	0.5 (0.9)		
Median (Q1, Q3)	0.0 (0.0, 0.1)	0.3 (0.1, 0.6)	0.2 (0.1, 0.5)		
(Min, Max)	(0.0, 4.4)	(0.0, 6.9)	(0.0, 6.9)		
Missing	20 (29.9%)	7 (3.2%)	27 (9.4%)		
Insulin				1.82 (1.46, 2.25)	<0.001
Mean (SD)	11.3 (10.1)	19.0 (17.3)	17.5 (16.5)		
Median (Q1, Q3)	7.7 (5.6, 12.2)	15.4 (10.6, 21.8)	13.9 (8.6, 20.5)		
(Min, Max)	(3.4, 52.0)	(3.2, 150.0)	(3.2, 150.0)		
Missing	20 (29.9%)	25 (11.4%)	45 (15.7%)		
Glucose				1.03 (0.99, 1.07)	0.117
Mean (SD)	86.7 (9.0)	88.8 (15.3)	88.4 (14.3)		
Median (Q1, Q3)	87.0 (83.0, 93.0)	87.0 (83.0, 92.0)	87.0 (83.0, 92.0)		
(Min, Max)	(64.0, 108.0)	(69.0, 264.0)	(64.0, 264.0)		
Missing	18 (26.9%)	5 (2.3%)	23 (8.0%)		
Systolic Blood Pressure				1.04 (1.02, 1.07)	<0.001
Mean (SD)	110.9 (10.9)	113.0 (9.7)	112.5 (10.0)		
Median (Q1, Q3)	110.0 (102.0, 120.0)	112.0 (108.0, 120.0)	112.0 (106.0, 120.0)		
(Min, Max)	(90.0, 151.0)	(80.0, 140.0)	(80.0, 151.0)		
Missing	0 (0%)	1 (0.5%)	1 (0.3%)		
Diastolic Blood Pressure					
Mean (SD)	65.7 (8.1)	68.9 (7.7)	68.1 (7.9)	1.07 (1.04, 1.11)	<0.001
Median (Q1, Q3)	64.0 (60.0, 70.5)	70.0 (62.0, 73.5)	68.0 (62.0, 72.0)		
(Min, Max)	(48.0, 82.0)	(50.0, 96.0)	(48.0, 96.0)		
Missing	0 (0%)	1 (0.5%)	1 (0.3%)		

636 **Table 2. Gut microbial taxa significantly associated with percent adipose tissue in mice at 2**

637 **weeks post FMT**

Family	Genus	Species	ASV	Effect Size	P adj*
Lachnospiraceae	*Hungatella*	*hathewayii*	ASV_51	3.59	0.001
Oscillospiraceae	*Colidextribacter*	NA	ASV_203	-2.90	0.05
Eggerthellaceae	*Gordonibacter*	NA	ASV_200	-2.71	0.02
Lachnospiraceae	*NA*	NA	ASV_119	15.78	0.02
Akkermansiaceae	*Akkermansia*	NA	ASV_4	3.06	0.05

639 *P values adjusted for multiple comparisons

640
641

FIGURE LEGENDS

Figure 1. Significant metabolic changes are associated with clinical measures of obesity in

adolescents. (**A**) POMMS study overview depicting the inclusion criteria, sampling schedule for

both the healthy weight control (HWC) and participants with obesity (OB). (**B-D**) Linear

regression analysis adjusted for age, race and sex of participant. See Statistical Analysis

description in Methods for details. (**B**) Targeted serum metabolites associated with %95th BMI,

(**C**) Hemoglobin A1c (HbA1c), (**D**) Homeostatic Insulin Resistance score (HOMA-IR), at

baseline, or (**E**) C-Reactive Protein (CRP), at baseline. For (**B-E)**, metabolites above the dotted

line are considered significantly associated with the noted clinical measure. Higher levels of

metabolites in the right upper quadrant are significantly associated with higher levels of the

clinical measure. In comparison, higher levels of metabolites in the left upper quadrant are

significantly associated with lower levels of the clinical measure. %95th BMI is defined as the

percent of the BMI above the 95th percentile. Diagram in (A) was created with BioRender.com.

Figure 2. Branched chain amino acids (BCAA) and related metabolite levels are sex

dependent, significantly different in HWC v OB cohorts, and unique to adolescents with

obesity. (**A**) BCAA related metabolism pathway. Valine (VAL), Leucine (LEU) and Isoleucine

(ILE) are reversibly transaminated by the branched chain amino acid transferase (BCAT2) in the

mitochondria to their respective ketoacids ketoisovalerate (KIV), ketoisocaproate (KIC) and

ketomethylvalerate (KMV). The amino group removed from the BCAA is transferred to α-

ketoglutarate (α-KG), yielding glutamate (GLU). The ketoacids can then be irreversibly

hydrolyzed by the branched chain ketoacid dehydrogenase (BCKDH) where BCAA derived

carbons can then enter the TCA cycle or contribute to lipogenesis. When BCAA are elevated, as

in obesity, excess BCAA increases BCAT2 activity which could result in an increased nitrogen

load, especially in muscle tissues. This load can be relieved, most likely via coordinated action of

serine dehydratase, serine hydroxymethyltransferase, and glycine acyltransferase. Resulting

increased metabolites, such as glutamine (GLN) and acylglycine can be secreted from the

affected tissues. ALA, alanine; PYR, pyruvate. (**B-J**) Levels of serum amino acids and keto acids

associated with BCAA and alanine-pyruvate metabolism in HWC v OB cohorts divided by sex.

Box plots represent mean and standard deviation. Statistics were performed on mean metabolite

values following log transformation, and P values result from Mann-Whitney tests and are

corrected for multiple comparisons. **, $P<0.01$; ***, $P<0.001$; ****, $P<0.0001$. Diagram in (**A**)

was created with BioRender.com.

Figure 3. Sex-dependent differences in serum ketoacids are less evident in younger children

than in more mature adolescents. Log-transformed levels of serum metabolites tested for

significance in an overall interaction and between (**A**) sex and HWC v OB status; (**B**) Tanner

(puberty) stage and HWC v OB status; and (**C**) Young age (9 y or younger) versus older age

metabolites and sex. Only significant metabolites are shown, $P \leq 0.05$, after adjustment for race

and multiple comparisons. Complete metabolite results are shown in Supplemental Tables 2, 2.1,

3, and 3.1). See Statistical Analysis methods for details.

Figure 4. **Several gut microbial taxa and predicted enzymatic functions are associated with**

clinical variables at baseline. (**A**) Abundance of microbial species determined by fecal

metagenomic sequencing that were positively or negatively significantly associated with %95th

BMI at baseline. (**B**) Venn diagram showing shared and distinct numbers of fecal microbial

species associated with %95th BMI, insulin resistance score (HOMA-IR) and C-reactive protein

(CRP) levels at baseline. (**C**) Linear regression correlation following dimensionality reduction

between co-varying microbial factors and clinical variables at baseline. Factors are named for

prominent taxa within each cluster, and the underlying taxa and weights in each cluster are listed

in Supplemental Tables 4.1-4.4.

Figure 5. **Fecal microbial transplants from adolescent POMMS study participants did not**

significantly affect weight gain in recipient mice but did influence serum metabolites. (**A**)

Experimental design. Groups of 3-5 six-week-old male germ-free mice were weighed and

gavaged with a slurry of baseline fecal material from one of 5 HWC or 9 OB POMMS

participants. Mice were weighed every 3-4 days and sacrificed at 14 days post gavage. (**B**)

Average weight and standard deviation of each group of mice over the 2 weeks post gavage

period. (**C**) Mouse serum metabolites associated with percent weight gain over the FMT

incubation period. Labeled dots above the dashed line represent metabolites significantly

associated with less weight gain over time following linear regression analysis. (**D**) Mean percent

weight gain of all mice grouped by donor (HWC v OB) at baseline. (**E**) Mean epidydimal fat pad

weight grouped by donor at baseline. (**F**) Mean percent epidydimal fat pad weight grouped by

donor at baseline. (**G**) Fecal microbial taxa were identified by 16S rRNA gene sequencing. ASV

significantly associated ($P \leq 0.05$ after adjustment for multiple comparisons) with clustered

mouse serum metabolites (Supplemental Figure S6) using ANCOM-BC (32) are shown on the

heatmap. Clusters are described by the predominant metabolite species in each cluster. Each

taxon in the heatmap represents a unique ASV identified to the lowest classification possible.

BCAA, branched chain amino acids; AC, acylcarnitines. Diagram in (**A**) was created with

BioRender.com.

Figure 6. Serum aromatic amino acids increase with BMI and HOMA-IR scores over the 6

month observational study period, while several even chain acylcarnitines and glycine go

up with clinical improvements and reduction in CRP. (**A**) Absolute change in %95th BMI in

OB cohort participants over the observational study period. (**B**) Percent change in HOMA-IR

over the observational study period. (**C**) Graph of change in %95th BMI and percent change in

HOMA-IR over the observational study period. (**D-F**) Estimated coefficients for metabolite

levels associated with change in %95th BMI (**D**), Percent change in HOMA-IR (**E**), or change in

CRP (**F**) after adjusting for age, race, sex, and baseline measurement. For (**A-C**), all participants

with net reduction in the indicated measure are labeled by observational trial treatment type. For

(D-F), acylcarnitines are labeled in black, amino acids are labeled in purple, and ketoacids are

labeled in green.

Figure 7. Microbial taxa associated with longitudinal outcomes. (**A**) Differential abundance

of microbial taxa at baseline associated with change in %95th BMI over the 6-month

observational period. (**B**) Venn diagram of microbial taxa shared between changes in clinical

outcomes over the study period. See Statistical Analysis methods for details.

Figure 8. Obesity in adolescence is characterized by unique transitional metabolomic and

microbiome features. Lines indicate the direction of microbiome and metabolome features in

individuals with obesity relative to age matched healthy weight (HW) individuals. Several of

these features display changing relationships with OB status across the lifespan. Dashed lines

indicate age ranges where there is currently missing data for that feature. We found that while

high BMI is associated with high levels of serum BCAA, BCKA differences between OB and

HW adolescents are sex dependent and pronounced in later stages of puberty. Further, serum

measures of insulin resistance increased during adolescence for nearly all participants during our

observational study, regardless of whether the participant lost weight, but there was no difference

in fasting glucose between OB and HWC at baseline. We observed no significant difference in

the ability of adolescent microbiome to transmit more weight gain to germ free mice, while

evidence suggests that microbiome transplant from adult donors with OB leads to more weight

gain in recipients. Evidence for each of these associations is cited in the text.

LITERATURE CITED

1.   Felig P, Marliss E, and Cahill GF, Jr. Plasma amino acid levels and insulin secretion in
obesity. *N Engl J Med.* 1969;281(15):811-6.
2.   Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, et al. A branched-
chain amino acid-related metabolic signature that differentiates obese and lean humans
and contributes to insulin resistance. *Cell Metab.* 2009;9(4):311-26.
3.   Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al. Metabolite
profiles and the risk of developing diabetes. *Nat Med.* 2011;17(4):448-53.
4.   Batch BC, Shah SH, Newgard CB, Turer CB, Haynes C, Bain JR, et al. Branched chain
amino acids are novel biomarkers for discrimination of metabolic wellness. *Metabolism.*
2013;62(7):961-9.
5.   Menni C, Fauman E, Erte I, Perry JR, Kastenmuller G, Shin SY, et al. Biomarkers for
type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach.
Diabetes. 2013;62(12):4270-6.
6.   Glynn EL, Piner LW, Huffman KM, Slentz CA, Elliot-Penry L, AbouAssi H, et al.
Impact of combined resistance and aerobic exercise training on branched-chain amino
acid turnover, glycine metabolism and insulin sensitivity in overweight humans.
Diabetologia. 2015;58(10):2324-35.
7.   Hernandez-Alvarez MI, Diaz-Ramos A, Berdasco M, Cobb J, Planet E, Cooper D, et al.
Early-onset and classical forms of type 2 diabetes show impaired expression of genes
involved in muscle branched-chain amino acids metabolism. *Sci Rep.* 2017;7(1):13850.
8.   Kobayashi R, Shimomura Y, Murakami T, Nakai N, Fujitsuka N, Otsuka M, et al.
Gender difference in regulation of branched-chain amino acid catabolism. *Biochem J.*
1997;327 (Pt 2)(Pt 2):449-53.
9.   Neinast M, Murashige D, and Arany Z. Branched Chain Amino Acids. *Annu Rev Physiol.*
2019;81:139-64.
10.   White PJ, Lapworth AL, An J, Wang L, McGarrah RW, Stevens RD, et al. Branched-
chain amino acid restriction in Zucker-fatty rats improves muscle insulin sensitivity by
enhancing efficiency of fatty acid oxidation and acyl-glycine export. *Mol Metab.*
2016;5(7):538-51.
11.   Morris C, O'Grada C, Ryan M, Roche HM, Gibney MJ, Gibney ER, et al. The
relationship between BMI and metabolomic profiles: a focus on amino acids. *Proc Nutr*
Soc. 2012;71(4):634-8.
12.   Mihalik SJ, Goodpaster BH, Kelley DE, Chace DH, Vockley J, Toledo FG, et al.
Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification
of a marker of glucolipotoxicity. *Obesity (Silver Spring).* 2010;18(9):1695-700.
13.   Juonala M, Magnussen CG, Berenson GS, Venn A, Burns TL, Sabin MA, et al.
Childhood adiposity, adult adiposity, and cardiovascular risk factors. *N Engl J Med.*
2011;365(20):1876-85.
14.   Tirosh A, Shai I, Afek A, Dubnov-Raz G, Ayalon N, Gordon B, et al. Adolescent BMI
trajectory and risk of diabetes versus coronary disease. *N Engl J Med.*
2011;364(14):1315-25.
15.   Butte NF, Liu Y, Zakeri IF, Mohney RP, Mehta N, Voruganti VS, et al. Global
metabolomic profiling targeting childhood obesity in the Hispanic population. *Am J Clin*
Nutr. 2015;102(2):256-67.

16. Gumus Balikcioglu P, Jachthuber Trub C, Balikcioglu M, Ilkayeva O, White PJ,
Muehlbauer M, et al. Branched-chain alpha-keto acids and glutamate/glutamine:
Biomarkers of insulin resistance in childhood obesity. *Endocrinol Diabetes Metab*. 2022.
17. Hernandez N, Lokhnygina Y, Ramaker ME, Ilkayeva O, Muehlbauer MJ, Crawford ML,
et al. Sex Differences in Branched-chain Amino Acid and Tryptophan Metabolism and
Pathogenesis of Youth-onset Type 2 Diabetes. *J Clin Endocrinol Metab*.
2024;109(4):e1345-e58.
18. Cani PD, and Van Hul M. Gut microbiota in overweight and obesity: crosstalk with
adipose tissue. *Nat Rev Gastroenterol Hepatol*. 2024;21(3):164-83.
19. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, et al. Gut microbiota from
twins discordant for obesity modulate metabolism in mice. *Science*.
2013;341(6150):1241214.
20. Tremaroli V, Karlsson F, Werling M, Stahlman M, Kovatcheva-Datchary P, Olbers T, et
al. Roux-en-Y Gastric Bypass and Vertical Banded Gastroplasty Induce Long-Term
Changes on the Human Gut Microbiome Contributing to Fat Mass Regulation. *Cell
Metab*. 2015;22(2):228-38.
21. Turnbaugh PJ, Backhed F, Fulton L, and Gordon JI. Diet-induced obesity is linked to
marked but reversible alterations in the mouse distal gut microbiome. *Cell Host Microbe*.
2008;3(4):213-23.
22. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core
gut microbiome in obese and lean twins. *Nature*. 2009;457(7228):480-4.
23. McCann JR, Bihlmeyer NA, Roche K, Catherine C, Jawahar J, Kwee LC, et al. The
Pediatric Obesity Microbiome and Metabolism Study (POMMS): Methods, Baseline
Data, and Early Insights. *Obesity (Silver Spring)*. 2021;29(3):569-78.
24. Hampl SE, Hassink SG, Skinner AC, Armstrong SC, Barlow SE, Bolling CF, et al.
Clinical Practice Guideline for the Evaluation and Treatment of Children and
Adolescents With Obesity. *Pediatrics*. 2023;151(2).
25. Girousse A, Tavernier G, Valle C, Moro C, Mejhert N, Dinel AL, et al. Partial inhibition
of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without
alteration of fat mass. *PLoS Biol*. 2013;11(2):e1001485.
26. Jehan S, Zizi F, Pandi-Perumal SR, McFarlane SI, Jean-Louis G, and Myers AK. Energy
imbalance: obesity, associated comorbidities, prevention, management and public health
implications. *Adv Obes Weight Manag Control*. 2020;10(5):146-61.
27. Bramante CT, Palzer EF, Rudser KD, Ryder JR, Fox CK, Bomberg EM, et al. BMI
metrics and their association with adiposity, cardiometabolic risk factors, and biomarkers
in children and adolescents. *Int J Obes (Lond)*. 2022;46(2):359-65.
28. Kelsey MM, Zeitler PS, Drews K, and Chan CL. Normal Hemoglobin A1c Variability in
Early Adolescence: Adult Criteria for Prediabetes Should Be Applied with Caution. *J
Pediatr*. 2020;216:232-5.
29. Emmanuel M, and Bokor BR. *StatPearls*. Treasure Island (FL); 2023.
30. Armstrong SC, Windom M, Bihlmeyer NA, Li JS, Shah SH, Story M, et al. Rationale and
design of "Hearts & Parks": study protocol for a pragmatic randomized clinical trial of an
integrated clinic-community intervention to treat pediatric obesity. *BMC Pediatr*.
2020;20(1):308.
31. Fernandes AD, Reid JN, Macklaim JM, McMurrough TA, Edgell DR, and Gloor GB.
Unifying the analysis of high-throughput sequencing datasets: characterizing RNA-seq,

16S rRNA gene sequencing and selective growth experiments by compositional data
analysis. *Microbiome.* 2014;2:15.

32. Lin H, Eggesbo M, and Peddada SD. Linear and nonlinear correlation estimators unveil
undescribed taxa interactions in microbiome data. *Nat Commun.* 2022;13(1):4946.

33. Martin BD, Witten D, and Willis AD. Modeling Microbial Abundances and Dysbiosis
with Beta-Binomial Regression. *Ann Appl Stat.* 2020;14(1):94-115.

34. Pedersen HK, Gudmundsdottir V, Nielsen HB, Hyotylainen T, Nielsen T, Jensen BA, et
al. Human gut microbes impact host serum metabolome and insulin sensitivity. *Nature.*
2016;535(7612):376-81.

35. Li S, Ma X, Mei H, Chang X, He P, Sun L, et al. Association between gut microbiota and
short-chain fatty acids in children with obesity. *Sci Rep.* 2025;15(1):483.

36. Zhang Z, Mocanu V, Cai C, Dang J, Slater L, Deehan EC, et al. Impact of Fecal
Microbiota Transplantation on Obesity and Metabolic Syndrome-A Systematic Review.
Nutrients. 2019;11(10).

37. Mardinoglu A, Gogg S, Lotta LA, Stancakova A, Nerstedt A, Boren J, et al. Elevated
Plasma Levels of 3-Hydroxyisobutyric Acid Are Associated With Incident Type 2
Diabetes. *EBioMedicine.* 2018;27:151-5.

38. Cook JS, Hoffman RP, Stene MA, and Hansen JR. Effects of maturational stage on
insulin sensitivity during puberty. *J Clin Endocrinol Metab.* 1993;77(3):725-30.

39. Moran A, Jacobs DR, Jr., Steinberger J, Hong CP, Prineas R, Luepker R, et al. Insulin
resistance during puberty: results from clamp studies in 357 children. *Diabetes.*
1999;48(10):2039-44.

40. Travers SH, Jeffers BW, Bloch CA, Hill JO, and Eckel RH. Gender and Tanner stage
differences in body composition and insulin sensitivity in early pubertal children. *J Clin*
Endocrinol Metab. 1995;80(1):172-8.

41. Newgard CB. Interplay between lipids and branched-chain amino acids in development
of insulin resistance. *Cell Metab.* 2012;15(5):606-14.

42. Palmer ND, Stevens RD, Antinozzi PA, Anderson A, Bergman RN, Wagenknecht LE, et
al. Metabolomic profile associated with insulin resistance and conversion to diabetes in
the Insulin Resistance Atherosclerosis Study. *J Clin Endocrinol Metab.*
2015;100(3):E463-8.

43. Shah SH, Crosslin DR, Haynes CS, Nelson S, Turer CB, Stevens RD, et al. Branched-
chain amino acid levels are associated with improvement in insulin resistance with
weight loss. *Diabetologia.* 2012;55(2):321-30.

44. Laferrere B, Reilly D, Arias S, Swerdlow N, Gorroochurn P, Bawa B, et al. Differential
metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic
subjects despite identical weight loss. *Sci Transl Med.* 2011;3(80):80re2.

45. Magkos F, Bradley D, Schweitzer GG, Finck BN, Eagon JC, Ilkayeva O, et al. Effect of
Roux-en-Y gastric bypass and laparoscopic adjustable gastric banding on branched-chain
amino acid metabolism. *Diabetes.* 2013;62(8):2757-61.

46. She P, Van Horn C, Reid T, Hutson SM, Cooney RN, and Lynch CJ. Obesity-related
elevations in plasma leucine are associated with alterations in enzymes involved in
branched-chain amino acid metabolism. *Am J Physiol Endocrinol Metab.*
2007;293(6):E1552-63.

883 47. White PJ, McGarrah RW, Grimsrud PA, Tso SC, Yang WH, Haldeman JM, et al. The
884   BCKDH Kinase and Phosphatase Integrate BCAA and Lipid Metabolism via Regulation
885   of ATP-Citrate Lyase. *Cell Metab*. 2018;27(6):1281-93 e7.
886 48. Bacha F, El-Ayash H, Mohamad M, Sharma S, Puyau M, Kanchi R, et al. Distinct Amino
887   Acid Profile Characterizes Youth With or at Risk for Type 2 Diabetes. *Diabetes*.
888   2024;73(4):628-36.
889 49. Krumsiek J, Mittelstrass K, Do KT, Stuckler F, Ried J, Adamski J, et al. Gender-specific
890   pathway differences in the human serum metabolome. *Metabolomics*. 2015;11(6):1815-
891   33.
892 50. Lamont LS, McCullough AJ, and Kalhan SC. Gender differences in leucine, but not
893   lysine, kinetics. *J Appl Physiol (1985)*. 2001;91(1):357-62.
894 51. Newbern D, Gumus Balikcioglu P, Balikcioglu M, Bain J, Muehlbauer M, Stevens R, et
895   al. Sex differences in biomarkers associated with insulin resistance in obese adolescents:
896   metabolomic profiling and principal components analysis. *J Clin Endocrinol Metab*.
897   2014;99(12):4730-9.
898 52. Gaggini M, Carli F, Rosso C, Buzzigoli E, Marietti M, Della Latta V, et al. Altered
899   amino acid concentrations in NAFLD: Impact of obesity and insulin resistance.
900   *Hepatology*. 2018;67(1):145-58.
901 53. Labonte CC, Farsijani S, Marliss EB, Gougeon R, Morais JA, Pereira S, et al. Plasma
902   Amino Acids vs Conventional Predictors of Insulin Resistance Measured by the
903   Hyperinsulinemic Clamp. *J Endocr Soc*. 2017;1(7):861-73.
904 54. Takashina C, Tsujino I, Watanabe T, Sakaue S, Ikeda D, Yamada A, et al. Associations
905   among the plasma amino acid profile, obesity, and glucose metabolism in Japanese adults
906   with normal glucose tolerance. *Nutr Metab (Lond)*. 2016;13:5.
907 55. Gralka E, Luchinat C, Tenori L, Ernst B, Thurnheer M, and Schultes B. Metabolomic
908   fingerprint of severe obesity is dynamically affected by bariatric surgery in a procedure-
909   dependent manner. *Am J Clin Nutr*. 2015;102(6):1313-22.
910 56. Tulipani S, Griffin J, Palau-Rodriguez M, Mora-Cubillos X, Bernal-Lopez RM,
911   Tinahones FJ, et al. Metabolomics-guided insights on bariatric surgery versus behavioral
912   interventions for weight loss. *Obesity (Silver Spring)*. 2016;24(12):2451-66.
913 57. White PJ, Lapworth AL, McGarrah RW, Kwee LC, Crown SB, Ilkayeva O, et al.
914   Muscle-Liver Trafficking of BCAA-Derived Nitrogen Underlies Obesity-Related
915   Glycine Depletion. *Cell Rep*. 2020;33(6):108375.
916 58. Zhang S, Zeng X, Ren M, Mao X, and Qiao S. Novel metabolic and physiological
917   functions of branched chain amino acids: a review. *J Anim Sci Biotechnol*. 2017;8:10.
918 59. Hosseinkhani S, Salari P, Bandarian F, Asadi M, Shirani S, Najjar N, et al. Circulating
919   amino acids and acylcarnitines correlated with different CAC score ranges in diabetic
920   postmenopausal women using LC-MS/MS based metabolomics approach. *BMC Endocr
921   Disord*. 2022;22(1):186.
922 60. Kanmani S, Kwon M, Shin MK, and Kim MK. Association of C-Reactive Protein with
923   Risk of Developing Type 2 Diabetes Mellitus, and Role of Obesity and Hypertension: A
924   Large Population-Based Korean Cohort Study. *Sci Rep*. 2019;9(1):4573.
925 61. Lee CC, Adler AI, Sandhu MS, Sharp SJ, Forouhi NG, Erqou S, et al. Association of C-
926   reactive protein with type 2 diabetes: prospective analysis and meta-analysis.
927   *Diabetologia*. 2009;52(6):1040-7.

62. Tam CS, Clement K, Baur LA, and Tordjman J. Obesity and low-grade inflammation: a
paediatric perspective. *Obes Rev.* 2010;11(2):118-26.
63. Nappo A, Iacoviello L, Fraterman A, Gonzalez-Gil EM, Hadjigeorgiou C, Marild S, et al.
High-sensitivity C-reactive protein is a predictive factor of adiposity in children: results
of the identification and prevention of dietary- and lifestyle-induced health effects in
children and infants (IDEFICS) study. *J Am Heart Assoc.* 2013;2(3):e000101.
64. Selvin E, Paynter NP, and Erlinger TP. The effect of weight loss on C-reactive protein: a
systematic review. *Arch Intern Med.* 2007;167(1):31-9.
65. McCann JR, and Rawls JF. Essential Amino Acid Metabolites as Chemical Mediators of
Host-Microbe Interaction in the Gut. *Annu Rev Microbiol.* 2023;77:479-97.
66. Alves A, Bassot A, Bulteau AL, Pirola L, and Morio B. Glycine Metabolism and Its
Alterations in Obesity and Metabolic Diseases. *Nutrients.* 2019;11(6).
67. Dai ZL, Wu G, and Zhu WY. Amino acid metabolism in intestinal bacteria: links
between gut ecology and host health. *Front Biosci (Landmark Ed).* 2011;16(5):1768-86.
68. Agans R, Rigsbee L, Kenche H, Michail S, Khamis HJ, and Paliy O. Distal gut
microbiota of adolescent children is different from that of adults. *FEMS Microbiol Ecol.*
2011;77(2):404-12.
69. Cox AJ, West NP, and Cripps AW. Obesity, inflammation, and the gut microbiota.
Lancet Diabetes Endocrinol. 2015;3(3):207-15.
70. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, and Gordon JI. Obesity
alters gut microbial ecology. *Proc Natl Acad Sci U S A.* 2005;102(31):11070-5.
71. Del Chierico F, Abbatini F, Russo A, Quagliariello A, Reddel S, Capoccia D, et al. Gut
Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential
Patterns. *Front Microbiol.* 2018;9:1210.
72. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, and Gordon JI. An
obesity-associated gut microbiome with increased capacity for energy harvest. *Nature.*
2006;444(7122):1027-31.
73. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, and Turner RC.
Homeostasis model assessment: insulin resistance and beta-cell function from fasting
plasma glucose and insulin concentrations in man. *Diabetologia.* 1985;28(7):412-9.
74. Olson KC, Chen G, and Lynch CJ. Quantification of branched-chain keto acids in tissue
by ultra fast liquid chromatography-mass spectrometry. *Anal Biochem.* 2013;439(2):116-
22.
75. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, and Holmes SP. DADA2:
High-resolution sample inference from Illumina amplicon data. *Nat Methods.*
2016;13(7):581-3.
76. Goodman AL, Kallstrom G, Faith JJ, Reyes A, Moore A, Dantas G, et al. Extensive
personal human gut microbiota culture collections characterized and manipulated in
gnotobiotic mice. *Proc Natl Acad Sci U S A.* 2011;108(15):6252-7.
77. Wei R, Wang J, Su M, Jia E, Chen S, Chen T, et al. Missing Value Imputation Approach
for Mass Spectrometry-based Metabolomics Data. *Sci Rep.* 2018;8(1):663.
78. Menzel P, Ng KL, and Krogh A. Fast and sensitive taxonomic classification for
metagenomics with Kaiju. *Nat Commun.* 2016;7:11257.
79. Beghini F, McIver LJ, Blanco-Miguez A, Dubois L, Asnicar F, Maharjan S, et al.
Integrating taxonomic, functional, and strain-level profiling of diverse microbial
communities with bioBakery 3. *Elife.* 2021;10.

80. Chin Fatt CR, Asbury S, Jha MK, Minhajuddin A, Sethuram S, Mayes T, et al.
Leveraging the microbiome to understand clinical heterogeneity in depression: findings
from the T-RAD study. *Transl Psychiatry*. 2023;13(1):139.
977

Figure 1. Significant metabolic changes are associated with clinical measures of obesity in adolescents. (A) POMMS study overview depicting the inclusion criteria, sampling schedule for both the healthy weight control (HWC) and participants with obesity (OB). **(B-D)** Linear regression analysis adjusted for age, race and sex of participant. See Statistical Analysis description in Methods for details. **(B)** Targeted serum metabolites associated with %95th BMI, **(C)** Hemoglobin A1c (HbA1c), (D) Homeostatic Insulin Resistance score (HOMA-IR), at baseline, or **(E)** C-Reactive Protein (CRP), at baseline. For B-E, metabolites above the dotted line are considered significantly associated with the noted clinical measure. Higher levels of metabolites in the right upper quadrant are significantly associated with higher levels of the clinical measure. In comparison, higher levels of metabolites in the left upper quadrant are significantly associated with lower levels of the clinical measure. %95th BMI is defined as the percent of the BMI above the 95th percentile. Diagram in part **(A)** was created with Biorender.

Figure 2. Branched chain amino acids (BCAA) and related metabolite levels are sex dependent, significantly different in HWC v OB cohorts, and unique to adolescents with obesity. (A) BCAA related metabolism pathway. Valine (VAL), Leucine (LEU) and Isoleucine (ILE) are reversibly transaminated by the branched chain amino acid transferase (BCAT2) in the mitochondria to their respective ketoacids keto-isovalerate (KIV), ketoisocaproate (KIC) and ketomethylvalerate (KMV). The amino group removed from the BCAA is transferred to α-ketoglutarate (α-KG), yielding glutamate (GLU). The ketoacids can then be irreversibly hydrolyzed by the branched chain ketoacid dehydrogenase (BCKDH) where BCAA derived carbons can then enter the TCA cycle or contribute to lipogenesis. When BCAA are elevated, as in obesity, excess BCAA increases BCAT2 activity which could result in an increased nitrogen load, especially in muscle tissues. This load can be relieved, most likely via coordinated action of serine dehydratase, serine hydroxymethyltransferase, and glycine acyltransferase. Resulting increased metabolites, such as glutamine (GLN) and acylglycine can be secreted from the affected tissues. ALA, alanine; PYR, pyruvate. **(B-J)** Levels of serum amino acids and keto acids associated with BCAA and alanine-pyruvate metabolism in HWC v OB cohorts divided by sex. Box plots represent mean and standard deviation. Statistics were performed on mean metabolite values following log transformation, and P values result from Mann-Whitney tests and are corrected for multiple comparisons. **, P<0.01; ***, P<0.001; ****, P<0.0001.

Figure 3. Sex-dependent differences in serum ketoacids are less evident in younger children than in more mature adolescents. Log-transformed levels of serum metabolites tested for significance in an overall interaction and between **(A)** sex and HWC v OB status; **(B)** Tanner (puberty) stage and HWC v OB status; and **(C)** Young age (9 y or younger) versus older age metabolites and sex. Only significant metabolites are shown, P < 0.05, after adjustment for race and multiple comparisons. Complete metabolite results are shown in Supplemental Tables 2, 2.1, 3, and 3.1). See Statistical Analysis methods for details.

Figure 4. Several gut microbial taxa and predicted enzymatic functions are associated with clinical variables at baseline. (A) Abundance of microbial species determined by fecal metagenomic sequencing that were positively or negatively significantly associated with %95th BMI at baseline. **(B)** Venn diagram showing shared and distinct numbers of fecal microbial species associated with %95th BMI, insulin resistance score (HOMA-IR) and C-reactive protein (CRP) levels at baseline. **(C)** Linear regression correlation following dimensionality reduction between co-varying microbial factors and clinical variables at baseline. Factors are named for prominent taxa within each cluster, and the underlying taxa and weights in each cluster is listed in Supplemental Tables 4.1-4.4.

Figure 5. Fecal microbial transplants from adolescent POMMS study participants did not significantly affect weight gain in recipient mice but did influence serum metabolites. (A) Experimental design. Groups of 3-5 six-week-old male germ-free mice were weighed and gavaged with a slurry of baseline fecal material from one of 5 HWC or 9 OB POMMS participants. Mice were weighed every 3-4 days and sacrificed at 14 days post gavage. **(B)** Average weight and standard deviation of each group of mice over the 2 weeks post gavage period. **(C)** Mouse serum metabolites associated with percent weight gain over the FMT incubation period. Labeled dots above the dashed line represent metabolites significantly associated with less weight gain over time following linear regression analysis. **(D)** Mean percent weight gain of all mice grouped by donor (HWC v OB) at baseline. **(E)** Mean epidydimal fat pad weight grouped by donor at baseline. **(F)** Mean percent epidydimal fat pad weight grouped by donor at baseline. **(G)** Fecal microbial taxa were identified by 16S rRNA gene sequencing. ASV significantly associated (P < 0.05 after adjustment for multiple comparisons) with clustered mouse serum metabolites (Supplemental Figure S6) using ANCOM-BC (32) are shown on the heatmap. Clusters are described by the predominant metabolite species in each cluster. Each taxon in the heatmap represents a unique ASV identified to the lowest classification possible. BCAA, branched chain amino acids; AC, acylcarnitines. Diagram in part **(A)** was created with BioRender.com.

Figure 6. Serum aromatic amino acids increase with BMI and HOMA-IR scores over the 6 month observational study period, while several even chain acylcarnitines and glycine go up with clinical improvements and reduction in CRP. **(A)** Absolute change in %95th BMI in OB cohort participants over the observational study period. **(B)** Percent change in HOMA-IR over the observational study period. **(C)** Graph of change in %95th BMI and percent change in HOMA-IR over the observational study period. **(D-F)** Estimated coefficients for metabolite levels associated with change in %95th BMI **(D),** Percent change in HOMA-IR **(E)**, or change in CRP **(F)** after adjusting for age, race, sex, and baseline measurement. For **(A-C)**, all participants with net reduction in the indicated measure are labeled by observational trial treatment type. For **(D-F)**, acylcarnitines are labeled in black, amino acids are labeled in purple, and ketoacids are labeled in green.

A

B

Figure 7. Microbial taxa associated with longitudinal outcomes. (A) Differential abundance of microbial taxa at baseline associated with change in %95th BMI over the 6-month observational period. (B) Venn diagram of microbial taxa shared between changes in clinical outcomes over the study period. See Statistical Analysis methods for details.

Figure 8. Obesity in adolescence is characterized by unique and potentially transitional metabolomic and microbiome features. Lines indicate the direction of microbiome and metabolome features in individuals with obesity relative to age matched healthy weight (HW) individuals. Several of these features display changing relationships with OB status across the lifespan. Dashed lines indicate age ranges where there is currently missing data for that feature. We found that while high BMI is associated with high levels of serum BCAA, BCKA differences between OB and HW adolescents are sex dependent and pronounced in later stages of puberty. Further, serum measures of insulin resistance increased during adolescence for nearly all participants during our observational study, regardless of whether the participant lost weight, but there was no difference in fasting glucose between OB and HWC at baseline. We saw no significant difference in the ability of adolescent microbiome to transmit more weight gain to germ free mice, while evidence suggests that microbiome transplant from adult donors with OB leads to more weight gain in recipients. Evidence for each of these associations is cited in the text.